Total income of the company has increased from Rs. 3,536.02 crore for the quarter ended June 30, 2014 to Rs. 3,770.25 crore for the quarter ended June 30, 2015.
Dr. Reddy's Laboratories Has Launched Three Generic Drugs in the US Market
Dr. Reddy's Laboratories has launched three generic drugs in the US market which are used to treat central nervous system disorders.
Dr. Reddy's Laboratories has launched three generic drugs in the US market which are used to treat central nervous system disorders.
FDA Lifts Import Alert on Dr. Reddy's Mexican Facility
Dr. Reddy's Laboratories has announced that the US Food and Drug Administration has lifted an import alert on its Mexican facility.
Dr. Reddy's Laboratories has announced that the US Food and Drug Administration has lifted an import alert on its Mexican facility.
USDA Approval for Australian Bioequivalent Sodium Injection Procured by Dr. Reddy's Laboratories
Dr. Reddy's has received final approval from the United States Food and Drug Administration (USFDA) for Dr. Reddy's ANDA for Fondaparinux Sodium Injection
Dr. Reddy's has received final approval from the United States Food and Drug Administration (USFDA) for Dr. Reddy's ANDA for Fondaparinux Sodium Injection
Chest Pain Drug Withdrawn by Dr. Reddy's Laboratories From US Market
Dr Reddy's volunteered to withdraw 13,560 bottles of metoprolol succinate tablets from the United States following the failure of dissolution tests, said the US Food and Drug Administration.
Dr Reddy's volunteered to withdraw 13,560 bottles of metoprolol succinate tablets from the United States following the failure of dissolution tests, said the US Food and Drug Administration.
